Notícias e Atividades da Repertoire Immune Medicines

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Repertoire Immune Medicines

• Torben Nissen, Chief Executive Officer
• Doug Cole, Director
• JC Gutierrez-Ramos, Director

Recentes movimentos de executivos em Repertoire Immune Medicines

• Robert Andtbacka, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 5 de junho de 2025).

Criar um alerta
para seguir os movimentos de executivos da Repertoire Immune Medicines.

Repertoire Immune Medicines possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Repertoire Immune Medicines

• Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic • Repertoire Immune Medicines
• Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease • Repertoire Immune Medicines
• Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • Repertoire Immune Medicines
• Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics • Repertoire Immune Medicines
• Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer • Repertoire Immune Medicines
• New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer • Repertoire Immune Medicines
• Repertoire® Immune Medicines Enters New Research Collaboration to Discover The T Cell Response to Therapy in HPV-Associated Cancers • Repertoire Immune Medicines
• Repertoire® Immune Medicines Identifies Novel Immune Targets in Pathogenesis of Type 1 Diabetes • Repertoire Immune Medicines
• Preclinical Research Published in SCIENCE ADVANCES Demonstrates Repertoire Immune Medicines’ Cell-tethering Technology Delivers Potent Interleukin-12 Directly to Solid Tumors Potentially Improving Effectiveness of Cellular Immunotherapies • Repertoire Imm
• https://s3.us-east-1.amazonaws.com/repertoire-assets.investeddigital.com/downloads/Repertoire-SITC-PRESS-RELEASE_FINAL_6-Nov-2020.pdf
• View more press releases Close

Redes sociais sobre Repertoire Immune Medicines

• Repertoire Immune Medicines na Wikipedia, Google News e Yahoo Finance
• Repertoire Immune Medicines na LinkedIn, Twitter e YouTube